Odonate, Inc.

MUN:4OD Stock Report

Market Cap: €43.8m

This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

Odonate Therapeutics Management

Management criteria checks 3/4

Key information

Kevin Tang

Chief executive officer

n/a

Total compensation

CEO salary percentagen/a
CEO tenure9.8yrs
CEO ownershipn/a
Management average tenure6.1yrs
Board average tenure5.3yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Kevin Tang's remuneration changed compared to Odonate Therapeutics's earnings?
DateTotal CompensationSalaryCompany Earnings
Sep 30 2021n/an/a

-US$102m

Jun 30 2021n/an/a

-US$119m

Mar 31 2021n/an/a

-US$130m

Dec 31 2020US$1US$1

-US$126m

Sep 30 2020n/an/a

-US$122m

Jun 30 2020n/an/a

-US$118m

Mar 31 2020n/an/a

-US$113m

Dec 31 2019US$1US$1

-US$112m

Sep 30 2019n/an/a

-US$113m

Jun 30 2019n/an/a

-US$110m

Mar 31 2019n/an/a

-US$101m

Dec 31 2018US$1US$1

-US$89m

Sep 30 2018n/an/a

-US$76m

Jun 30 2018n/an/a

-US$62m

Mar 31 2018n/an/a

-US$47m

Dec 31 2017US$1US$1

-US$33m

Sep 30 2017n/an/a

-US$19m

Jun 30 2017n/an/a

-US$10m

Mar 31 2017n/an/a

-US$6m

Dec 31 2016US$1US$1

-US$3m

Compensation vs Market: Insufficient data to establish whether Kevin's total compensation is reasonable compared to companies of similar size in the German market.

Compensation vs Earnings: Kevin's compensation has been consistent with company performance over the past year.

CEO

Kevin Tang (55 yo)

9.8yrs

Tenure

US$1

Compensation

Mr. Kevin C. Tang serves as Director at Tetraphase Pharmaceuticals, Inc. since July 28, 2020. He has been the Chairman and Chief Executive Officer at Odonate Therapeutics, Inc. since 2013. He served as the...

Leadership Team

NamePositionTenureCompensationOwnership
Kevin Tang
Chairman & CEO9.8yrsUS$1.00no data
Michael Hearne
CFO & Principal Accounting Officer4yrsUS$572.17k0.0089%
€ 3.9k
Ryan Cole
Senior Vice President of Operationsno datano datano data
Steven Pfeiffer
Senior Vice President of Technical Operations6.3yrsno datano data
Thomas Wei
Chief Scientific Officer4yrsno datano data
Stewart Kroll
Chief Development Officer6.1yrsno datano data
Tracey McKennon
Senior Vice President of Quality Assuranceno datano datano data
Jennifer Schroeder
Senior Vice President of Program Management & Technologyno datano datano data
Kim Ma
Senior Vice President of Clinical Operationsno datano datano data

6.1yrs

Average Tenure

55yo

Average Age

Experienced Management: 4OD's management team is seasoned and experienced (6.1 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Kevin Tang
Chairman & CEO9.8yrsUS$1.00no data
Laura Douglass
Independent Director3.9yrsUS$249.44k0%
€ 0
Aaron Davis
Independent Director5.9yrsno data1.51%
€ 663.4k
Craig Johnson
Independent Director5.3yrsUS$274.44k0.010%
€ 4.5k
Robert Rosen
Director5.3yrsUS$249.44k0%
€ 0

5.3yrs

Average Tenure

57yo

Average Age

Experienced Board: 4OD's board of directors are considered experienced (5.3 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2022/11/08 01:52
End of Day Share Price 2022/08/11 00:00
Earnings2021/09/30
Annual Earnings2020/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Odonate, Inc. is covered by 3 analysts. of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Dana FlandersGoldman Sachs
Michael YeeJefferies LLC
Eric SchmidtTD Cowen